Reviewer Disclosures
| Reviewer | Employment | Research Grant | Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness | Ownership Interest | Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Eric R. Bates |
University of Michigan |
None | None | None | None | None | None | None |
| N.A. Mark Estes III |
New England Medical Center |
None | None | None | None | None | None | None |
| Leonard S. Gettes |
University of North Carolina at Chapel Hill |
None | None | None | None | None | Philips Electronics* |
None |
| Federico Gentile |
Centro Medico Diagnostico |
None | None | None | None | None | None | None |
| Robert A. Harrington |
Duke University |
None | None | None | None | None | None | None |
| Barry J. Maron |
Minneapolis Heart Institute Foundation |
None | None | None | None | None | None | None |
| Debabrata Mukherjee |
University of Kentucky |
Abbott Vascular*; Schering-Plough* |
None | None | None | None | None | None |
| Robert S. Rosenson |
University of Michigan |
Abbott†; Anthera†; AstraZeneca† |
None | Abbott†; AstraZeneca†; Daiichi Sankyo† |
None | LipoScience† | AstraZeneca†; Abbott*; Anthera*; Daiichi Sankyo*; LipoScience*; Novo Nordisk*; Roche† |
None |
| Andrea M. Russo |
Cooper University |
Medtronic*; St. Jude*; Biotronic*; Boston Scientific* |
Medtronic*; St. Jude*; Boston Scientific* |
|||||
| Melvin Scheinman |
University of California, San Francisco |
None | None | None | None | None | None | None |
| Kathryn Wood |
Duke University |
None | None | None | None | None | None | None |
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if 1) the person receives $10 000 or more during any 12-month period or 5% or more of the person’s gross income; or 2) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.